var data={"title":"Potassium citrate and citric acid (powder or solution): Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Potassium citrate and citric acid (powder or solution): Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6833?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=potassium-citrate-and-citric-acid-powder-or-solution-drug-information\" class=\"drug drug_general\">see &quot;Potassium citrate and citric acid (powder or solution): Drug information&quot;</a> and <a href=\"topic.htm?path=potassium-citrate-and-citric-acid-powder-or-solution-patient-drug-information\" class=\"drug drug_patient\">see &quot;Potassium citrate and citric acid (powder or solution): Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212994\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Cytra-K;</li>\n      <li>Virtrate-K [DSC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032304\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Alkalinizing Agent, Oral</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F12874698\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1 mL of oral solution contains 2 mEq of bicarbonate and 2 mEq of potassium; 1 packet of crystals contains 30 mEq of bicarbonate and 30 mEq of potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Systemic alkalinization; chronic:</b> Limited data available: Oral: 2 to 3 mEq bicarbonate/kg/<b>day</b> (1 to 1.5 mL/kg/<b>day</b>) in 3 to 4 divided doses (Cloherty 2012; Kliegman 2007)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032322\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=potassium-citrate-and-citric-acid-powder-or-solution-drug-information\" class=\"drug drug_general\">see &quot;Potassium citrate and citric acid (powder or solution): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> 1 mL of oral solution contains 2 mEq of bicarbonate and 2 mEq of potassium; 1 packet of crystals contains 30 mEq of bicarbonate and 30 mEq of potassium.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric<b>: Note</b>: Individualize dose as determined by disease and patient-specific targets.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Systemic alkalinization; chronic:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Volume-based dosing: Children and Adolescents: Oral: 5 to 15 mL (10 to 30 mEq bicarbonate) per dose after meals and at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Weight-directed dosing (mEq bicarbonate/kg): Limited data available: Infants, Children, and Adolescents: Oral: 2 to 3 mEq bicarbonate/kg/<b>day</b> (1 to 1.5 mL/kg/<b>day</b>) in 3 to 4 divided doses; adjust dose to targeted serum bicarbonate levels; typical adult doses do not exceed 60 mEq/dose (30 mL/dose) (Kliegman 2007)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Renal tubular acidosis (RTA), distal; type 1: </b>Limited data available: Dose requirements may vary with age; Infants, Children, and Adolescents: Oral: Usual dose: 3 to 4 mEq bicarbonate/kg/<b>day </b>(1.5 to 2 mL/kg/<b>day</b>) in 3 divided doses; in small trials and reported clinical experience, this dosing has been shown to correct most associated urine abnormalities (Domrongkitchaiporn 2002; Santos 1986; Soriano 2002; Tapaney-Olarn 2002). <b>Note:</b> May be used in combination with sodium citrate formulations to manage proximal RTA (type 2) but not as monotherapy due to high therapeutic alkali requirement for proximal RTA and corresponding potassium load created (Soriano 2002).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Urine alkalinization, urolithiasis (cystinuria, uricosuria, hypocitraturia): </b>Limited data available: Infants, Children, and Adolescents: Oral: Reported range: 0.5 to 4 mEq bicarbonate/kg/<b>day</b> (0.25 to 2 mL/kg/<b>day</b>) in 4 divided doses; titrate to target pH (dependent on stone composition) (Copelvitch 2012; Penido 2015; Santos-Victoriano 1998). Per the manufacturer, in adults, when used for urine alkalinization, doses of 20 to 30 mEq bicarbonate (10 to 15 mL) administered 4 times daily typically maintain urinary pH 7 to 7.6.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>S</b><b>ystemic alkalinizer, Acidosis, Gout (adjuvant): </b>Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Powder: One packet (30 mEq bicarbonate) dissolved in 6 oz water after meals and at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solution: 15 to 30 mL (30 to 60 mEq bicarbonate) per dose after meals and at bedtime</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Note:</b> When using to alkalinize the urine, 10 to 15 mL (20 to 30 mEq bicarbonate) doses given 4 times daily typically maintain urinary pH 7 to 7.6.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Use is contraindicated in patients with anuria or severe renal impairment with oliguria or azotemia.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51154207\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Use is contraindicated in patients with anuria or severe renal impairment with oliguria or azotemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51154208\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212996\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span><p>(For additional information <a href=\"topic.htm?path=potassium-citrate-and-citric-acid-powder-or-solution-drug-information\" class=\"drug drug_general\">see &quot;Potassium citrate and citric acid (powder or solution): Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Systemic alkalinizer, Acidosis, Gout (adjuvant):</b> Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder: One packet dissolved in water  4 times daily; adjust dose to urinary pH</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution: 10 to 30 mL 4 times daily; adjust dose based on urinary pH</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50992078\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling. Use is contraindicated in patients with anuria or severe renal impairment with oliguria or azotemia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50989273\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212981\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder for solution, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cytra-K: Potassium citrate monohydrate 3300 mg and citric acid monohydrate 1002 mg per packet (100s) [sugar free; fruit-punch flavor; each packet contains potassium 30 mEq equivalent to bicarbonate 30 mEq]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Solution, oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cytra-K: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (480 mL) [ethanol free, sugar free; contains propylene glycol; cherry flavor; contains potassium 2 mEq/mL equivalent to bicarbonate 2 mEq /mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Virtrate-K: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (480 mL [DSC]) [sugar free; contains propylene glycol; cherry flavor; contains potassium 2 mEq/mL equivalent to bicarbonate 2 mEq /mL]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: Potassium citrate monohydrate 1100 mg and citric acid monohydrate 334 mg per 5 mL (473 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212969\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032326\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Dose should be diluted prior to administration to minimize injury due to high concentration of potassium; administer after meals and at bedtime to prevent saline laxative effect; may follow dose with additional water if necessary; dose may be chilled to improve palatability. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212991\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at 20&deg;C to 25&deg;C (68&deg;F to 77&deg;F). Protect from excessive heat or freezing. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1032305\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">As long-term therapy to alkalinize the urine for control and/or dissolution of uric acid and cystine calculi of the urinary tract [FDA approved in pediatric patients (age not specified) and adults]; treatment of chronic metabolic acidosis secondary to chronic renal insufficiency or syndrome of renal tubular acidosis when use of sodium salt is undesirable [FDA approved in pediatric patients (age not specified) and adults]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27867370\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Polycitra may be confused with Bicitra</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212987\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to any ingredient of the formulation, severe renal insufficiency with oliguria or azotemia; potassium-restricted diet; untreated Addison disease; adynamia episodica hereditaria; acute dehydration; heat cramps; anuria; severe myocardial damage; hyperkalemia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212972\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; GI effects: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation and/or obstruction requiring surgical intervention.  Some fatal cases have been reported.  Discontinue immediately if abdominal pain, distension, nausea, vomiting or GI bleeding occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatic impairment: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients in hepatic failure.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated  in severe renal impairment with oliguria or azotemia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Severely ill: Citrate is converted to bicarbonate in the liver; this conversion may be blocked in patients who are severely ill or in shock.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates.  See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Propylene glycol: Some dosage forms may contain propylene glycol; large amounts are potentially toxic and have been associated hyperosmolality, lactic acidosis, seizures and respiratory depression; use caution (AAP [&quot;Inactive&quot; 1997]; Zar, 2007).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Administration: Dilute with water to minimize GI injury; administer after meals to minimize saline laxative effect.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26535374\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some dosage forms may contain propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3,000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; toxicities have also been reported in children and adults including hyperosmolality, lactic acidosis, seizures, and respiratory depression; use caution (AAP 1997; Shehab 2009).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299920\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212976\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=16457&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Aliskiren: Potassium Salts may enhance the hyperkalemic effect of Aliskiren. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Alpha-/Beta-Agonists (Indirect-Acting): Alkalinizing Agents may increase the serum concentration of Alpha-/Beta-Agonists (Indirect-Acting). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aluminum Hydroxide: Citric Acid Derivatives may increase the absorption of Aluminum Hydroxide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amantadine: Alkalinizing Agents may increase the serum concentration of Amantadine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphetamines: Alkalinizing Agents may decrease the excretion of Amphetamines. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Potassium Salts may enhance the hyperkalemic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Citrate.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparin: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Heparins (Low Molecular Weight): May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Mecamylamine: Alkalinizing Agents may increase the serum concentration of Mecamylamine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Memantine: Alkalinizing Agents may increase the serum concentration of Memantine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hyperkalemic effect of Potassium Salts.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QuiNINE: Alkalinizing Agents may increase the serum concentration of QuiNINE. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14287310\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to potassium citrate monograph for information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49165642\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Serum bicarbonate, potassium, BUN, Cr; LFTs; urine pH and other urinary indices based on clinical condition</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212986\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: &ge;95% via hepatic oxidation to bicarbonate; may be impaired in patients with hepatic failure, in shock, or who are severely ill; citric acid is metabolized to CO<sub>2</sub> and H<sub>2</sub>O</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&lt; 5% unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F212988\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Pack</b> (Taron-Crystals Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">3300-1002 mg (100): $85.48</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Potassium Citrate-Citric Acid Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1100-334 mg/5 mL (473 mL): $50.85</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14190110\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Litiasin (PE);</li>\n      <li>Urocitra-C Pwd (KR)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics Committee on Drugs. &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol - United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291.  <a>http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/6810084 /pubmed\" target=\"_blank\" id=\"6810084 \">6810084 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cloherty JP, Eichenwald EC, Hansen AR, Stark AR, eds. <i>Manual of Neonatal Care</i>. 7th edition. Philadelphia, PA: Lippincott Williams &amp; Wilkins; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Copelovitch, L. Urolithiasis in children: medical approach. <i>Pediatr Clin North Am</i>. 2012;59(4):881-896.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/22857835/pubmed\" target=\"_blank\" id=\"22857835\">22857835</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cystra-K Crystals granule for solution (potassium citrate and citric acid) [prescribing information]. Morristown, NJ: Cypress Pharmaceutical, Inc; September 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cystra-K oral solution (potassium citrate and citric acid) [prescribing information]. Madison, MS: Cypress Pharmaceutical, Inc; December 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Domrongkitchaiporn S, Khositseth S, Stitchantrakul W, Tapaneya-olarn W, Radinahamed P. Dosage of potassium citrate in the correction of urinary abnormalities in pediatric distal renal tubular acidosis patients. <i>Am J Kidney Dis</i>. 2002;39(2):383-391.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/11840381/pubmed\" target=\"_blank\" id=\"11840381\">11840381</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Behrman RE, Jenson HB, et al, eds. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders Elsevier; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Penido MG, Tavares Mde S. Pediatric primary urolithiasis: symptoms, medical management and prevention strategies. <i>World J Nephrol</i>. 2015;4(4):444-454.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/26380196/pubmed\" target=\"_blank\" id=\"26380196\">26380196</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos F, Chan JC. Renal tubular acidosis in children. Diagnosis, treatment and prognosis. <i>Am J Nephrol</i>. 1986;6(4):289-295.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/3777038/pubmed\" target=\"_blank\" id=\"3777038\">3777038</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Santos-Victoriano M, Brouhard BH, Cunningham RJ 3rd. Renal stone disease in children. <i>Clin Pediatr (Phila)</i>. 1998;37(10):583-599.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/9793728/pubmed\" target=\"_blank\" id=\"9793728\">9793728</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Shehab N, Lewis CL, Streetman DD, Donn SM. Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates. <i>Pediatr Crit Care Med</i>. 2009;10(2):256-259.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/19188870/pubmed\" target=\"_blank\" id=\"19188870\">19188870</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Soriano J. Renal tubular acidosis: the clinical entity. <i>J Am Soc Nephrol</i>. 2002;13(8):2160-2170.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/12138150/pubmed\" target=\"_blank\" id=\"12138150\">12138150</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tapaneya-Olarn W, Khositseth S, Tapaneya-Olarn C, et al. The optimal dose of potassium citrate in the treatment of children with distal renal tubular acidosis. <i>J Med Assoc Thai</i>. 2002;85(Suppl 4):S1143-1149.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/12549788/pubmed\" target=\"_blank\" id=\"12549788\">12549788</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Virtrate-K (potassium citrate and citric acid) [prescribing information]. Tampa, FL: Virtus Pharmaceuticals, LLC; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zar T, Graeber C, Perazella MA. Recognition, treatment, and prevention of propylene glycol toxicity. <i>Semin Dial</i>. 2007;20(3):217-219.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/potassium-citrate-and-citric-acid-powder-or-solution-pediatric-drug-information/abstract-text/17555487 /pubmed\" target=\"_blank\" id=\"17555487 \">17555487 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 16457 Version 71.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F212994\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1032304\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F12874698\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F1032322\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51154207\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51154208\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F212996\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50992078\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50989273\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F212981\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F212969\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1032326\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F212991\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1032305\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27867370\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F212987\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F212972\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F26535374\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299920\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F212976\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14287310\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F49165642\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F212986\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F212988\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F14190110\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/16457|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=potassium-citrate-and-citric-acid-powder-or-solution-drug-information\" class=\"drug drug_general\">Potassium citrate and citric acid (powder or solution): Drug information</a></li><li><a href=\"topic.htm?path=potassium-citrate-and-citric-acid-powder-or-solution-patient-drug-information\" class=\"drug drug_patient\">Potassium citrate and citric acid (powder or solution): Patient drug information</a></li></ul></div></div>","javascript":null}